Related Experiment Video
Updated: Jul 6, 2026
06:08
Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Rosiglitazone maleate 0.25-hydrate: a pseudopolymorphic form.
Silvia L Cuffini1, Sonia Faudone, Maribel Ferro
1Agencia Córdoba Ciencia, Córdoba, Argentina. scuffini@yahoo.com
Summary
The crystal structure of rosiglitazone maleate 0.25-hydrate reveals a unique packing arrangement. Hydrogen-bonded tetramers form chains, differing from previous forms.
Area of Science:
- Crystallography
- Medicinal Chemistry
- Solid-State Chemistry
Background:
- Rosiglitazone maleate is a medication used to treat type 2 diabetes.
- Understanding the solid-state properties of drug molecules is crucial for formulation and bioavailability.
- Previous studies have characterized other forms of rosiglitazone maleate.
Purpose of the Study:
- To determine the crystal structure of the 0.25-hydrated form of rosiglitazone maleate.
- To analyze the molecular geometry and packing arrangement in the unit cell.
- To compare the crystal structure with previously reported forms.
Main Methods:
- Single-crystal X-ray diffraction analysis.
- Analysis of crystallographic data to determine molecular and crystal structure.
- Comparison of structural features with related compounds.
Main Results:
- The 0.25-hydrated form of rosiglitazone maleate crystallizes as a racemate with two independent moieties in the unit cell.
- The cation geometry is similar to the hydrochloride salt.
- A distinct packing arrangement was observed, characterized by hydrogen-bonded tetramers forming weakly interacting chains.
Conclusions:
- The crystal structure of rosiglitazone maleate 0.25-hydrate exhibits unique hydrogen-bonding and packing motifs.
- These findings contribute to the understanding of the solid-state behavior of rosiglitazone maleate.
- The distinct crystal packing may influence the physicochemical properties and formulation of the drug.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...